New medication for moderate to severe hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This study tests a new injected medication (SPY072) for people with moderate to severe hidradenitis suppurativa (HS), a condition causing painful bumps and abscesses. The goal is to see if this treatment can reduce symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You've had HS symptoms for at least 6 months
- HS bumps or abscesses in at least 2 body areas (like armpits, groin, buttocks)
- You have at least 5 painful lumps or abscesses from HS
- You've tried at least one prescription HS treatment that didn't work well enough or caused side effects
- You don't have more than 20 draining tunnels (tracts that leak fluid)
- No other skin condition that could interfere with HS assessment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.
This trial tests a new drug called NAV-240 for people with hidradenitis suppurativa (HS) who have not had success with antibiotics. The goal is to see if the drug can reduce the number of painful lumps and improve symptoms.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.